Limits...
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Bottom Line: In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.We conclude that tumour blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumour site and specific type of cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH

Related in: MedlinePlus

Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746587&req=5

fig8: Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.

Mentions: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.


A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746587&req=5

fig8: Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
Mentions: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.

Bottom Line: In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.We conclude that tumour blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumour site and specific type of cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH
Related in: MedlinePlus